Efficacy and safety of etanercept in chronic immune-mediated disease

Expert Opinion on Drug Safety

Volumn 13, Issue 5, 2014, Pages 649-661

  Murdaca, Giuseppe ^a   Spanò, Francesca ^a   Contatore, Miriam ^a   Guastalla, Andrea ^a   Magnani, Ottavia ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Etanercept; Hepatitis B virus; Hepatitis C virus; Immune mediated diseases; Tuberculosis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CHRONIC DISEASE; CHRONIC IMMUNE MEDIATED DISEASE; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; IMMUNOPATHOLOGY; JUVENILE RHEUMATOID ARTHRITIS; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; HUMAN;

ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899083378     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.899579     Document Type: Article

References (116)

1. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
2. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
3. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-a guide for GPs. Aust Fam Physician 2007;36:1035-8
4. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
5. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
6. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
7. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
8. Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
9. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
10. Murdaca G, Spano F, Puppo F. Use of leflunomide plus TNF-alpha inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 2013;12(6):801-4
11. Murdaca G, F, Puppo F. Long term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol Res Rev 2013;5:43-9
12. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl 4):iv2-14
13. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
14. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7
15. Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
16. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45(5):490-7
17. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34(2):161-4
18. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(2):353-63
19. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152(6):1304-12
20. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349(21):2014-22
21. Murdaca G, Spano F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
22. Pichler WJ. Adverse side effects to biological agents. Allergy 2006;61(8):912-20
23. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75
24. Hatemi G, Melikoglu M, Ozbakir F, et al. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14(3):R147
25. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximabinduced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9
26. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohns disease: need for HPB-screening? World J Gastroenterol 2006;12:974-6
27. Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009;92:61-77
28. Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol 2012;31(6):931-6
29. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013;31(1):118-21
30. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59(7):C4480
31. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82
32. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF alpha blockers: safety and immunogenicity. Clin Immunol 2010;134(2):113-20
33. Murdaca G, Orsi A, Spano F, et al. Influenza and pneumococcal vaccinations of patients with Systemic Lupus Erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 2014;13(2):75-84
34. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
35. Mochizuki T, Momohara S, Yano K, et al. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. Mod Rheumatol 2013;23(5):994-1000
36. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63(3):373-82
37. Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival prospective, observational data. Rheumatology (Oxford) 2014;53(1):186-94
38. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93
39. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443-50
40. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009;68(7):1146-52
41. Benucci M, Saviola G, Baiardi P, et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol 2011;24(1):269-74
42. Minoretti P, Bruno A, Di Vito C, Emanuele E. Leflunomide as an antiatherogenic drug. Med Hypotheses 2007;68(5):1175-6
43. Murdaca G, Spano F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-alpha inhibitors. Redox Rep 2013;18(3):95-9.
44. Murdaca G, Spano F, Miglino M, Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
45. Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and Systemic Lupus Erythematosus. Hum Immunol 2008;69(8):510-12
46. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
47. Szekanecz Z, Kerekes G, Soltesz P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
48. Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in Systemic Lupus Erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
49. Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with Systemic Lupus Erythematosus. Ann N Y Acad Sci 2007;1108:121-6
50. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
51. Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
52. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
53. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80
54. Neregard P, Krishnamurthy A, Revu S, et al. Etanercept decreases synovial expression of tumour necrosis factoralpha and lymphotoxin-alpha in rheumatoid arthritis. Scand J Rheumatol 2013; Epub ahead of print
55. Senel S, Kisacik B, Ugan Y, et al. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 2011;30(10):1369-72
56. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
57. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9
58. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6
59. Kim HJ, Kammertoens T, Janke M, et al. Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells. J Immunol 2004;172:4037-47
60. Azevedo VF, Silva MB, Marinello DK, et al. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. Rev Bras Reumatol 2012;52(1):110-12
61. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford) 2008;47(3):376-7
62. Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006;45(8):1048-9
63. Houtman PM, Jansen TL, Blanken R. Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol 2006;12(6):321-2
64. Picchianti Diamanti A, Argento G, Podesta E, et al. Can the association of Ciclosporine A and Methotrexate maintain remission/low disease activity induced by etanercept in early Rheumatoid Arthritis patients? Evaluation by Magnetic Resonance Imaging. Int J Immunopathol Pharmacol 2012;25(1):301-5
65. Rigby WF, Mease PJ, Olech E, et al. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol 2013;40(5):599-604
66. Berthelot JM, Varin S, Cormier G, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 2007;74(2):144-7
67. Wada T, Son Y, Ozaki Y, et al. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. Mod Rheumatol 2012;22(6):824-30
68. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2
69. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342(11):763-9
70. Nielsen R, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92
71. Mori M, Takei S, Imagawa T, et al. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticularcourse juvenile idiopathic arthritis in Japan. Mod Rheumatol 2012;22:720-6
72. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2013;In press
73. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
74. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
75. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004;17:350-63
76. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for the treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ 2010;340:c147
77. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90
78. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
79. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72
80. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367(9504):29-35
81. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143(6):719-26
82. Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012;225(4):312-19
83. Girolomoni G, Altomare G, Ayala F, et al. Safety of anti-TNFalpha agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012;34(4):548-60
84. Maiette X. Lymphoma, rheumatoid arthritis, and TNF alpha antagonists. Joint Bone Spine 2010;77:195-7
85. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346(18):1349-56
86. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48(11):3230-6
87. De Stefano R, Frati E, De Quattro D, et al. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 2013;In press
88. van der Heijde D, Zack D, Wajdula J, et al. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. Scand J Rheumatol 2014;43(1):49-53
89. Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Expert Opin Biol Ther 2014;14(2):145-50
90. Gazi H, Pope JE, Clements P, et al. Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol 2007;34(3):501-9
91. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002;29:1867-73
92. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997;24(4):663-5.
93. Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum 2013;65(5):1347-56
94. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-8
95. Murdaca G, Spano F, Contatore M, et al. The potential use of TNF-alpha inhibitors in Systemic Sclerosis. Immunotherapy 2014; In press
96. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011;38(2):289-96
97. Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012;30(2 Suppl 71):S55-9
98. Bosello S, De Santis M, Tolusso B, et al. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143(12):918-20
99. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34(7):1636-7
100. Murdaca G, Spano F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf 2014; In press
101. Sakane T, Takeno M, Suzuki N, Inaba G. Behcets disease. N Engl J Med 1999;341(17):1284-91
102. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcets disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
103. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcets disease: a double blind, placebo controlled study. J Rheumatol 2005;32(1):98-105
104. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121(4):437-40
105. Zhang MF, Zhao C, Wen X, et al. The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept. Zhonghua Yan Ke Za Zhi 2010;46(2):145-50
106. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of Systemic Lupus Erythematosus. Semin Nephrol 1999;19:57-66
107. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in Systemic Lupus Erythematosus. Lupus 2005;14:189-91
108. Kikuchi H, Yamamoto T, Asako K, et al. Etanercept for the treatment of intractable hemophagocytic syndrome with Systemic Lupus Erythematosus. Mod Rheumatol 2012;22(2):308-11
109. Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 2008;18(1):72-5
110. De Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52(7):2192-201
111. De Bleeker JL, De Paepe B, Vanwalleghem IE, Schroder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 2002;58:1779-85
112. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8(2):104-6
113. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012;24(6):635-41
114. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59
115. Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328-34
116. Lee JY, Chang HK, Kim SK. Successful etanercept therapy for refractory sacroiliitis in a patient with ankylosing spondylitis and mixed connective tissue disease. Yonsei Med J 2008;49(1):159-62